W. O. West, M.D., (Associate); J. D. Ruff, M.D., (Associate); J. W. Yarbro, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The purpose of this study was to determine the efficacy and safety of hydroxyurea in the management of polycythemia vera. Hydroxyurea is effective in the control of chronic myelogenous leukemia. It has recently been reported to produce marked improvement in patients with refractory psoriasis. It is a specific inhibitor of deoxyribonucleic acid synthesis, acting at the level of conversion of ribonucleotides to deoxyribonucleotides, and its effectiveness as a inhibitor of erythropoiesis is demonstrated by the regular production of megaloblasts in the bone marrow. The earliest sign of therapy with hydroxyurea is a fall in the reticulocyte count which may be
West WO, Ruff JD, Yarbro JW. Response of Polycythemia to Treatment with a New Agent: Hydroxyurea.. Ann Intern Med. ;72:795. doi: 10.7326/0003-4819-72-5-795_3
Download citation file:
Published: Ann Intern Med. 1970;72(5):795.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use